NCT04721665

German SLD-Registry (Deutsches SLD-Register)

German SLD-Registry Characterization of Patients with Steatotic Liver Disease (SLD) in Germany - Phase 1 (observation of the Natural Course)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 5,000 (estimated)
• Sponsor: Leberstiftungs-GmbH Deutschland · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Characterization of patients with steatotic liver disease (SLD) The German SLD-Registry (Deutsches SLD-Register) a project of the German Liver Foundation (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland. The German NAFLD-Registry is financially supported by: Advanz Pharma Specialty Medicine Deutschland GmbH und Gilead Sciences GmbH (Grant to German Livber Foundation) sowie Novo Nordisk Pharma GmbH (directly via Leberstiftungs-GmbH).

Detailed description

The following data can be documented: * physical examination and vital parameters (e.g. age, weight) * comorbidities (e.g. diabetes mellitus, cardiovascular disease) * comedication (treatment of comorbidities related to SLD) * laboratory values (e.g. liver function tests, creatinine) * genetic variants (e.g. PNPLA3) * liver diagnostics (e.g. histological findings, sonographic findings) * lifestyle (alcohol consumption, physical activity) * health related quality of life (SF-36 questionnaire)

Conditions

• Steatotic Liver Disease

Timeline

• Start date: 2020-12-01
• Primary completion: 2036-11-30
• Completion: 2036-11-30
• First posted: 2021-01-25
• Last updated: 2025-03-06

Locations

14 sites across 1 country: Germany